SCLX
Scilex Holding Company NASDAQ Listed Mar 5, 2021$7.20
+4.96%
vs $6.86
Mkt Cap $61.1M
52w Low $2.62
24.5% of range
52w High $21.34
50d MA $4.91
200d MA $7.89
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-0.6x
ROE
180.0%
P/FCF
21.6x
RSI (14)
47.60
ATR (14)
$0.73
Beta
1.42
50d MA
$4.91
200d MA
$7.89
Avg Volume
108.5K
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
960 San Antonio Road · Palo Alto, CA 94303 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 10, 2026 | AMC | -0.47 | -4.60 | -878.7% | 6.80 | -4.4% | -12.4% | -0.5% | +6.2% | +4.6% | +4.7% | — |
| Nov 14, 2025 | AMC | -0.47 | -22.17 | -4617.0% | 17.69 | -4.0% | -12.3% | +5.5% | +4.9% | +10.3% | +18.8% | — |
| Aug 13, 2025 | AMC | -0.41 | -7.42 | -1709.8% | 21.00 | +4.3% | -17.3% | +4.1% | +7.2% | -7.3% | -2.2% | — |
| May 14, 2025 | AMC | -4.20 | -2.26 | +46.2% | 4.47 | -3.4% | -7.8% | +2.2% | +11.6% | +6.4% | -5.2% | — |
| Mar 31, 2025 | AMC | -0.10 | -0.25 | -150.0% | 8.70 | +5.4% | -4.5% | +25.3% | -4.3% | -9.3% | -3.7% | — |
| Jan 17, 2025 | AMC | -0.17 | -6.29 | -3600.0% | 15.72 | +0.4% | -5.8% | +4.0% | -2.3% | +2.4% | +4.5% | — |
| Aug 13, 2024 | AMC | -6.99 | -6.29 | +10.0% | 45.85 | +3.8% | -4.6% | -0.8% | -0.8% | +3.3% | -0.8% | — |
| May 13, 2024 | AMC | -4.20 | -9.09 | -116.4% | 28.17 | +1.3% | -0.6% | +2.3% | +6.3% | +3.4% | +34.4% | — |
| Mar 11, 2024 | AMC | -7.34 | -8.74 | -19.1% | 49.00 | +0.0% | -5.7% | +0.8% | +4.5% | -1.4% | +0.0% | — |
| Nov 14, 2023 | AMC | -5.94 | -22.03 | -270.9% | 43.05 | +3.3% | +2.4% | -15.1% | +0.0% | +2.8% | -13.8% | — |
| Aug 11, 2023 | AMC | — | -5.59 | — | 139.65 | +2.0% | -8.8% | -6.5% | +16.3% | +1.3% | -11.5% | — |
| May 12, 2023 | AMC | — | -0.22 | — | 189.35 | +1.3% | +22.9% | +0.8% | +3.7% | -0.7% | +3.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 11 | D. Boral Capital | Downgrade | Buy → Hold | — | $8.75 | $6.97 | -20.3% | -21.6% | -3.8% | +4.8% | -11.6% | -1.6% |
| Apr 2 | D. Boral Capital | Maintains | Buy → Buy | — | $8.31 | $8.23 | -1.0% | +25.3% | -4.3% | -9.3% | -3.7% | -0.7% |
| Feb 28 | D. Boral Capital | Maintains | Buy → Buy | — | $7.98 | $8.02 | +0.5% | +3.5% | +23.5% | +3.1% | +3.1% | +4.5% |
| Oct 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.95 | $34.48 | +1.6% | +1.0% | -1.0% | -5.8% | -2.3% | -3.5% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.35 | $59.85 | +6.2% | +33.5% | -14.9% | +7.1% | -10.7% | +2.3% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.20 | $40.25 | +2.7% | +18.8% | +8.3% | +3.5% | +8.1% | +33.5% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.25 | $39.20 | -2.6% | -5.2% | +3.7% | -4.4% | +5.6% | -2.6% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.69 | $30.87 | +4.0% | +1.4% | +0.6% | +6.0% | -7.7% | -2.0% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.25 | $48.30 | +2.2% | -3.7% | -9.2% | -3.4% | -4.4% | +0.9% |
No insider trades available.
8-K
Scilex Holding Company -- 8-K Filing
Jun 24
NT 10-Q
!! High
Scilex Holding Company -- Late Quarterly Report -- Distress Signal
May 15
8-K · 1.01
!! High
Scilex Holding Company -- 8-K 1.01: Material Agreement
Scilex Holding Company agreed to acquire Phoenix Asia Holdings Limited, expanding its portfolio through this stock acquisition deal.
May 5
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
A late annual report filing by Scilex suggests potential operational or administrative challenges that could indicate financial distress, warranting investor caution regarding SEC compliance and underlying business health.
Apr 1
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An executive's departure with a general release suggests potential internal turmoil or strategic disagreement, which could create uncertainty about company direction and leadership stability that investors should monitor closely.
Mar 17
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
I cannot provide a meaningful analysis because the filing excerpt contains only boilerplate signature language and exhibit references without substantive disclosure content about either BK or SCLX's business or operations.
Mar 13
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Scilex is pursuing legal action to recover $96 million in misappropriated Datavault AI shares, creating potential asset recovery upside but introducing litigation uncertainty and governance concerns for investors.
Mar 13
8-K · 1.01
! Medium
Scilex Holding Company -- 8-K 1.01: Equity Issuance
Scilex entered a warrant agreement with Oramed Pharmaceuticals, potentially diluting existing shareholders while providing Scilex capital through warrant exercise proceeds.
Feb 20
8-K · 1.01
!! High
Scilex Holding Company -- 8-K 1.01: Material Agreement
Scilex Holding Company declared a dividend with payment contingent on Board approval by the specified date, retaining the right to revoke it before the payment date.
Feb 3
8-K · 1.01
!! High
Scilex Holding Company -- 8-K 1.01: Material Agreement
Scilex Holding Company secured a $20 million agreement with Quantum Scan Holdings, potentially providing capital for operations or strategic initiatives, which could strengthen its financial position.
Feb 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 264,050 | $2M | New | Mar 2026 |
| 2 | Morgan Stanley | 29,212 | $356K | Reduced | Dec 2025 |
| 3 | Renaissance Technologies Llc | 36,864 | $246K | Reduced | Mar 2026 |
| 4 | Citigroup Inc | 19,846 | $242K | New | Dec 2025 |
| 5 | Ashton Thomas Private Wealth, Llc | 17,989 | $120K | — | Mar 2026 |
| 6 | Northern Trust Corp | 15,033 | $100K | — | Mar 2026 |
| 7 | Ubs Group Ag | 6,468 | $43K | Reduced | Mar 2026 |
| 8 | Creative Financial Designs Inc /adv | 1,853 | $12K | — | Mar 2026 |
| 9 | Royal Bank Of Canada | 1,596 | $11K | Added | Mar 2026 |
| 10 | Versant Capital Management, Inc | 761 | $5K | — | Mar 2026 |
| 11 | Ifp Advisors, Inc | 576 | $4K | New | Mar 2026 |
| 12 | Activest Wealth Management | 302 | $4K | — | Dec 2025 |
| 13 | Mcf Advisors Llc | 474 | $3K | — | Mar 2026 |
| 14 | Gamma Investing Llc | 116 | $773 | Reduced | Mar 2026 |
| 15 | Zurcher Kantonalbank (Zurich Cantonalbank) | 44 | $537 | — | Dec 2025 |
| 16 | S&t Bank/pa | 78 | $519 | New | Mar 2026 |
| 17 | Wells Fargo & Company/mn | 69 | $460 | New | Mar 2026 |
| 18 | Northwestern Mutual Wealth Management Co | 29 | $354 | — | Dec 2025 |
| 19 | New England Capital Financial Advisors Llc | 23 | $281 | — | Dec 2025 |
| 20 | Td Waterhouse Canada Inc. | 27 | $186 | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 14
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF | 17,630 | $117K | Mar 2026 |
| 2 | iShares Core S&P Total U.S. Stock Market ETF | 14,742 | $98K | Mar 2026 |
| 3 | MetLife Russell 2000 Index Portfolio | 627 | $4K | Mar 2026 |
| 4 | SIIT EXTENDED MARKET INDEX FUND | 344 | $3K | Feb 2026 |
| 5 | ProShares UltraPro Russell2000 | 139 | $1K | Feb 2026 |
| 6 | State Street Balanced Index Fund | 120 | $799 | Mar 2026 |
| 7 | ProShares Ultra Russell2000 | 91 | $746 | Feb 2026 |
| 8 | Avantis Total Equity Markets ETF | 80 | $657 | Feb 2026 |
| 9 | Dimensional US Core Equity Market ETF | 66 | $562 | Jan 2026 |
| 10 | LVIP Dimensional U.S. Core Equity 2 Fund | 39 | $260 | Mar 2026 |
| 11 | ULTRA SMALL CAP PROFUND | 29 | $250 | Jan 2026 |
| 12 | Guggenheim Active Allocation Fund | 14 | $115 | Feb 2026 |
| 13 | ProShares Hedge Replication ETF | 7 | $58 | Feb 2026 |
| 14 | SMALL-CAP PROFUND | 1 | $12 | Jan 2026 |
Valuation
Market Cap
$61.1M
Enterprise Value
$91.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
—
P/S
2.35x
P/FCF
21.57x
EV/EBITDA
—
Shares Out
11.0M
Financials (TTM)
Revenue
$33.9M
Net Income
-$419.7M
EBITDA
-$374.4M
Free Cash Flow
$3.7M
Op Cash Flow
$3.8M
EPS Basic
$-36.48
EPS Diluted
$-38.87
EPS Forward
$-0.89
Gross Margin
55.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$365.0M
Total Liab.
$576.7M
Total Equity
-$211.8M
Cash
$11.0M
LT Debt
$27.1M
Book Value/Sh
$-19.19
Debt/Equity
-0.64x
Current Ratio
0.08
Quick Ratio
0.07
Returns & Growth
ROE
180.0%
ROA
-102.5%
ROIC
1031.6%
Rev Growth YoY
-46.5%
EPS Growth YoY
-87.8%
Price Returns
2W
+36.9%
1M
-15.4%
3M
+8.4%
6M
-56.3%
12M
+73.8%
Technicals
52W High
$21.34
52W Low
$2.62
50d MA
$4.91
200d MA
$7.89
RSI (14)
47.60
ATR (14)
$0.73
Beta
1.42
Avg Volume
108K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 12:26am
· Source: financialmodelingprep.com